These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 10632996)

  • 1. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA.
    Niedrig M; Lademann M; Emmerich P; Lafrenz M
    Trop Med Int Health; 1999 Dec; 4(12):867-71. PubMed ID: 10632996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of MAC-ELISA for evaluation of yellow fever vaccination.
    Nogueira RM; Schatzmayr HG; Miagostovich MP; Cavalcanti SM; de Carvalho R
    Rev Inst Med Trop Sao Paulo; 1992; 34(5):447-50. PubMed ID: 1342109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the enzyme-linked immunosorbent assay (ELISA) with standard tests used to detect yellow fever virus antibodies.
    Deubel V; Mouly V; Salaun JJ; Adam C; Diop MM; Digoutte JP
    Am J Trop Med Hyg; 1983 May; 32(3):565-8. PubMed ID: 6344672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection.
    Reinhardt B; Jaspert R; Niedrig M; Kostner C; L'age-Stehr J
    J Med Virol; 1998 Oct; 56(2):159-67. PubMed ID: 9746073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of chloroquine prophylaxis on yellow fever vaccine antibody response: comparison of plaque reduction neutralization test and enzyme-linked immunosorbent assay.
    Barry M; Patterson JE; Tirrell S; Cullen MR; Shope RE
    Am J Trop Med Hyg; 1991 Jan; 44(1):79-82. PubMed ID: 1996743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological reactions in Rhesus monkeys inoculated with the 17D strain of yellow fever virus.
    GROOT H
    Bull World Health Organ; 1962; 27(6):709-15. PubMed ID: 13950709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine.
    GROOT H; RIBERIRO RB
    Bull World Health Organ; 1962; 27(6):699-707. PubMed ID: 13950710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Investigation of dengue virus and yellow fever virus seropositivities in blood donors from Central/Northern Anatolia, Turkey].
    Ergünay K; Saygan MB; Aydoğan S; Litzba N; Niedrig M; Pınar A; Us D
    Mikrobiyol Bul; 2010 Jul; 44(3):415-24. PubMed ID: 21063991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yellow fever haemagglutination-inhibiting, neutralising and IgM antibodies in vaccinated and unvaccinated residents of Ibadan, Nigeria.
    Omilabu SA; Adejumo JO; Olaleye OD; Fagbami AH; Baba SS
    Comp Immunol Microbiol Infect Dis; 1990; 13(2):95-100. PubMed ID: 2208973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.
    Poland JD; Calisher CH; Monath TP; Downs WG; Murphy K
    Bull World Health Organ; 1981; 59(6):895-900. PubMed ID: 6978196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination.
    Vázquez S; Valdés O; Pupo M; Delgado I; Alvarez M; Pelegrino JL; Guzmán MG
    J Virol Methods; 2003 Jun; 110(2):179-84. PubMed ID: 12798246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yellow fever outbreak in Ipetu-Ijesa: response after mass vaccination.
    Adu FD; Adeniji JA; Tomori O; Adelasoye A
    Rev Roum Virol; 1993; 44(1-2):3-7. PubMed ID: 8043476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1987 yellow fever epidemics in Oyo State, Nigeria: a survey for yellow fever virus haemagglutination inhibiting antibody in residents of two communities before and after the epidemics.
    Olaleye OD; Omilabu SA; Faseru O; Fagbami AH
    Virologie; 1988; 39(4):261-6. PubMed ID: 2851207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine.
    Kayser M; Klein H; Paasch I; Pilaski J; Blenk H; Heeg K
    J Med Virol; 1985 Sep; 17(1):35-45. PubMed ID: 2995571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative clinical study of a new 17D thermostable yellow fever vaccine.
    Roche JC; Jouan A; Brisou B; Rodhain R; Fritzell B; Hannoun C
    Vaccine; 1986 Sep; 4(3):163-5. PubMed ID: 3532602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological studies with group B arthropod-borne viruses. VI. Hemagglutination-inhibiting antibody responses to 17D yellow fever vaccine in human subjects with different degrees of complexity of pre-vaccination group B virus experience.
    Hatgi JN; Wisseman CL; Rosenzweig EC; Harrington BR; Kitaoka M
    Am J Trop Med Hyg; 1966 Jul; 15(4):601-10. PubMed ID: 5941178
    [No Abstract]   [Full Text] [Related]  

  • 17. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses.
    Brandriss MW; Schlesinger JJ; Walsh EE; Briselli M
    J Gen Virol; 1986 Feb; 67 ( Pt 2)():229-34. PubMed ID: 3944585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Arboviruses and lemurs in Madagascar: experimental infection of Lemur fulvus with attenuated strains of yellow fever virus].
    Rodhain F
    Bull Soc Pathol Exot Filiales; 1984; 77(3):255-62. PubMed ID: 6488418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein.
    Schlesinger JJ; Brandriss MW; Monath TP
    Virology; 1983 Feb; 125(1):8-17. PubMed ID: 6187129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limitations of the complement-fixation test for distinguishing naturally acquired from vaccine-induced yellow fever infection in flavivirus-hyperendemic areas.
    Monath TP; Craven RB; Muth DJ; Trautt CJ; Calisher CH; Fitzgerald SA
    Am J Trop Med Hyg; 1980 Jul; 29(4):624-34. PubMed ID: 7406113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.